Iodine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Iodine: From Antiseptic Use to Sjogren Syndrome
One-Sentence Summary
Iodine (DrugBank ID: DB05382) is an essential element with established antiseptic and antimicrobial properties, currently not registered as a pharmaceutical product in Singapore and carrying no formally approved therapeutic indications on file. The TxGNN model predicts it may be effective for Sjogren Syndrome, likely on the basis of the Sodium-Iodide Symporter (NIS) co-expressed in salivary glands and thyroid tissue. However, this prediction is supported by 0 clinical trials and 20 publications — all of which describe iodine as a contributing factor to salivary and lacrimal dysfunction rather than as a therapeutic agent for Sjogren Syndrome.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No approved indications on file |
| Predicted New Indication | Sjogren Syndrome |
| TxGNN Prediction Score | 94.09% |
| Evidence Level | L4 |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Iodine (DB05382) is an essential element whose pharmacological roles span antisepsis, thyroid hormone biosynthesis, and — in radioactive form (I-131) — targeted thyroid ablation. The TxGNN prediction most likely derives from the Sodium-Iodide Symporter (NIS), a membrane transporter co-expressed in both thyroid follicular epithelium and the ductal epithelium of salivary glands. A 2025 computational immunology study (PMID 41516079) identified shared NIS epitopes capable of triggering autoreactive T- and B-cell responses in both Hashimoto's thyroiditis and Sjogren's Syndrome, pointing to a convergent molecular pathway between these two autoimmune conditions.
Despite this structurally plausible link, the causal direction in all available evidence runs counter to a therapeutic role for iodine. High-dose radioactive iodine therapy for thyroid cancer causes iatrogenic sicca syndrome — salivary and lacrimal gland dysfunction closely resembling Sjogren's Syndrome — as a well-documented adverse effect (PMID 11337569). Multiple cross-sectional studies confirm a high comorbidity rate between primary Sjogren's Syndrome and autoimmune thyroid disease (PMID 7485204, PMID 12035942), but this reflects shared immune dysregulation, not a therapeutic effect of iodine on Sjogren's pathology.
In summary, the existing literature falls into three non-therapeutic categories: (1) radioactive iodine as a trigger of iatrogenic salivary/lacrimal dysfunction; (2) radiolabeled iodine as a diagnostic imaging tracer for salivary gland scintigraphy; and (3) epidemiological studies on autoimmune thyroid–Sjogren comorbidity. No published study has tested iodine as a treatment intervention in Sjogren's Syndrome, and the mechanistic hypothesis remains entirely speculative. The high TxGNN score most plausibly reflects shared knowledge-graph topology rather than a validated therapeutic relationship.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 41516079 | 2025 | Computational/Immunological | Int J Mol Sci | NIS epitopes computationally predicted to trigger autoimmune responses shared between Sjogren's Syndrome and Hashimoto's thyroiditis; provides the primary mechanistic hypothesis behind the TxGNN prediction |
| 35817018 | 2023 | Case Series/Review | ORL J Oto-Rhino-Laryngol | Sialendoscopy for chronic sialadenitis caused by Sjogren's syndrome and RAI therapy; iodine appears as a disease trigger, not a treatment |
| 11337569 | 2001 | Prospective Cohort | J Nucl Med | High-dose radioiodine therapy causes sicca syndrome (salivary and lacrimal dysfunction); up to 3-year follow-up confirms iodine as a causative agent |
| 24899999 | 2011 | Diagnostic Study | Nucl Med Mol Imaging | Salivary gland scintigraphy with radiolabeled iodine used to compare gland dysfunction in SS patients vs post-RAI thyroid cancer patients; iodine as diagnostic tracer |
| 30344785 | 2018 | Diagnostic Study | Nucl Med Mol Imaging | Quantitative SPECT/CT using Tc-99m pertechnetate to evaluate salivary gland dysfunction in Sjogren's Syndrome patients |
| 12035942 | 2002 | Cross-sectional | J Endocrinol Invest | Thyroid hormone autoantibodies more prevalent in primary Sjogren's syndrome than in Hashimoto's thyroiditis or Graves' disease; documents immune overlap |
| 7485204 | 1995 | Cross-sectional | Am J Med | Systematic evaluation of autoimmune thyroid disease prevalence and thyroid dysfunction in a primary Sjogren's syndrome cohort |
| 4951717 | 1967 | Clinical Study | Ann Rheum Dis | Early measurement of salivary flow rates and iodide trapping capacity in SS patients; among the first data linking iodide handling to SS gland pathology |
| 4965427 | 1967 | Clinical Study | Br J Ophthalmol | Early clinical documentation of the co-occurrence of Sjogren's syndrome and thyroid disease |
| 3261973 | 1988 | Case Report | Arch Intern Med | Silent thyroiditis in a Sjogren's syndrome patient with thyrotoxicosis and depressed radioactive iodine uptake; antinuclear antibody changes documented |
Singapore Market Information
Iodine (DB05382) is currently not registered as a pharmaceutical product in Singapore. No marketing authorizations or product licenses are on record. Any clinical use would require a new regulatory pathway from the ground up before the predicted indication could be pursued.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The entire body of available literature positions iodine as a causative agent of Sjogren's-like salivary and lacrimal dysfunction — not as a therapeutic intervention — and the mechanistic hypothesis connecting iodine to Sjogren's Syndrome treatment has not been tested in any clinical or preclinical setting.
To proceed, the following is needed:
- Mechanistic clarification: Establish whether iodine (at physiological or pharmacological doses, distinct from radioactive I-131) can modulate NIS-mediated autoimmune activity in salivary glands rather than damage gland epithelium
- Preclinical studies: In vitro and animal model experiments in Sjogren's-like models are required before any human study is warranted
- Safety data acquisition: TFDA package insert warnings and contraindications are currently unavailable and must be obtained (designated as a blocking data gap)
- MOA data from DrugBank: Formal mechanism of action documentation to confirm or refute the NIS hypothesis
- Expert consultation: Rheumatology and nuclear medicine input to assess whether any therapeutic dose window exists between iodine's known glandular toxicity and a hypothetical anti-autoimmune effect
- Directionality review: A formal knowledge-graph audit is recommended to flag this candidate as a potential false positive (iodine as pathogen, not therapeutic agent) before further resources are committed
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.